miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)

Oncotarget. 2015 Sep 8;6(26):22439-51. doi: 10.18632/oncotarget.4210.

Abstract

MicroRNA contribute to tumor radiation resistance, which is an important clinical problem, and thus we are interested in identifying and characterizing their function. We demonstrate that miR-620 contributes to radiation resistance in cancer cells by increasing proliferation, and decreasing the G2/M block. We identify the hydroxyprostaglandin dehydrogenase 15-(nicotinamide adenine dinucleotide) (HPGD/15-PGDH) tumor suppressor gene as a direct miR-620 target, which results in increased prostaglandin E2 (PGE2) levels. Furthermore, we show that siRNA targeting of HPGD or administration of exogenous PGE2 recapitulates radioresistance. Targeting of the EP2 receptor that responds to PGE2 using pharmacological or genetic approaches, abrogates radioresistance. Tumor xenograft experiments confirm that miR-620 increases proliferation and tumor radioresistance in vivo. Regulation of PGE2 levels via targeting of HPGD by miR-620 is an innovative manner by which a microRNA can induce radiation resistance.

Keywords: HPGD; PGE2; miR-620; radiation resistance.

MeSH terms

  • Animals
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics
  • Breast Neoplasms / radiotherapy
  • Breast Neoplasms / therapy
  • Cell Line, Tumor
  • Dinoprostone / metabolism
  • Dinoprostone / pharmacology
  • Female
  • Humans
  • Hydroxyprostaglandin Dehydrogenases / genetics
  • Hydroxyprostaglandin Dehydrogenases / metabolism*
  • Male
  • Mice
  • Mice, Nude
  • MicroRNAs / administration & dosage*
  • MicroRNAs / genetics
  • Neoplasms / enzymology
  • Neoplasms / genetics
  • Neoplasms / radiotherapy
  • Neoplasms / therapy*
  • Pancreatic Neoplasms / enzymology
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / radiotherapy
  • Pancreatic Neoplasms / therapy
  • Prostatic Neoplasms / enzymology
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / radiotherapy
  • Prostatic Neoplasms / therapy
  • RNA, Small Interfering / administration & dosage
  • RNA, Small Interfering / genetics
  • Radiation Tolerance / drug effects
  • Radiation Tolerance / genetics
  • Radiotherapy, Adjuvant
  • Transfection
  • Xenograft Model Antitumor Assays

Substances

  • MIRN620 microRNA, human
  • MicroRNAs
  • RNA, Small Interfering
  • Hydroxyprostaglandin Dehydrogenases
  • 15-hydroxyprostaglandin dehydrogenase
  • Dinoprostone